CN106795213B - 选择性地活化调节性t细胞用于治疗自身免疫病的分子 - Google Patents

选择性地活化调节性t细胞用于治疗自身免疫病的分子 Download PDF

Info

Publication number
CN106795213B
CN106795213B CN201580050979.6A CN201580050979A CN106795213B CN 106795213 B CN106795213 B CN 106795213B CN 201580050979 A CN201580050979 A CN 201580050979A CN 106795213 B CN106795213 B CN 106795213B
Authority
CN
China
Prior art keywords
leu
protein
lys
ser
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580050979.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN106795213A (zh
Inventor
杰弗里·格雷夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Delinia Inc
Original Assignee
Delinia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55163946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106795213(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Delinia Inc filed Critical Delinia Inc
Priority to CN202111371055.XA priority Critical patent/CN114133456A/zh
Publication of CN106795213A publication Critical patent/CN106795213A/zh
Application granted granted Critical
Publication of CN106795213B publication Critical patent/CN106795213B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201580050979.6A 2014-07-21 2015-07-20 选择性地活化调节性t细胞用于治疗自身免疫病的分子 Expired - Fee Related CN106795213B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111371055.XA CN114133456A (zh) 2014-07-21 2015-07-20 选择性地活化调节性t细胞用于治疗自身免疫病的分子

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461999241P 2014-07-21 2014-07-21
US61/999,241 2014-07-21
PCT/US2015/041177 WO2016014428A2 (en) 2014-07-21 2015-07-20 Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111371055.XA Division CN114133456A (zh) 2014-07-21 2015-07-20 选择性地活化调节性t细胞用于治疗自身免疫病的分子

Publications (2)

Publication Number Publication Date
CN106795213A CN106795213A (zh) 2017-05-31
CN106795213B true CN106795213B (zh) 2021-12-07

Family

ID=55163946

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111371055.XA Pending CN114133456A (zh) 2014-07-21 2015-07-20 选择性地活化调节性t细胞用于治疗自身免疫病的分子
CN201580050979.6A Expired - Fee Related CN106795213B (zh) 2014-07-21 2015-07-20 选择性地活化调节性t细胞用于治疗自身免疫病的分子

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202111371055.XA Pending CN114133456A (zh) 2014-07-21 2015-07-20 选择性地活化调节性t细胞用于治疗自身免疫病的分子

Country Status (22)

Country Link
US (6) US20170037102A1 (enExample)
EP (2) EP3172227B9 (enExample)
JP (2) JP6768633B2 (enExample)
KR (1) KR102493543B1 (enExample)
CN (2) CN114133456A (enExample)
AU (3) AU2015292889C1 (enExample)
CA (1) CA2954847A1 (enExample)
DK (1) DK3172227T3 (enExample)
EA (2) EA038361B1 (enExample)
ES (1) ES2763198T3 (enExample)
GB (1) GB2538666A (enExample)
HU (1) HUE046065T2 (enExample)
IL (3) IL289475B2 (enExample)
LT (1) LT3172227T (enExample)
MX (2) MX378790B (enExample)
PL (1) PL3172227T3 (enExample)
PT (1) PT3172227T (enExample)
RS (1) RS59789B1 (enExample)
SG (2) SG10202010158TA (enExample)
SI (1) SI3172227T1 (enExample)
WO (1) WO2016014428A2 (enExample)
ZA (1) ZA201700344B (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016500255A (ja) 2012-12-11 2016-01-12 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ ハイスループットなレセプター：リガンド同定の方法
IL289475B2 (en) * 2014-07-21 2023-10-01 Delinia Inc Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
PL3482766T3 (pl) 2014-08-11 2020-11-16 Delinia, Inc. Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznych
EA201792250A1 (ru) 2015-04-10 2018-05-31 Эмджен Инк. Мутеины интерлейкина-2 для роста регуляторных т-клеток
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
KR102687530B1 (ko) * 2016-05-04 2024-07-25 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
AU2017268348A1 (en) 2016-05-18 2018-10-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CA3022331A1 (en) 2016-05-18 2017-11-23 Albert Einstein College Of Medicine, Inc. Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof
JP2019532996A (ja) * 2016-11-08 2019-11-14 デリニア，インコーポレーテッド 自己免疫疾患を処置するためのｉｌ−２変異体
CA3044416A1 (en) * 2016-12-13 2018-06-21 Delinia, Inc. Multivalent regulatory t cell modulators
IL303806B2 (en) 2016-12-22 2024-05-01 Cue Biopharma Inc Multimeric polypeptides modulate T cells and methods for their use
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
AU2018234810B2 (en) 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
WO2018170168A1 (en) 2017-03-15 2018-09-20 Cue Biopharma, Inc. Methods for modulating an immune response
CN110678550B (zh) * 2017-03-29 2023-11-14 国立大学法人宫崎大学 长效肾上腺髓质素衍生物
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
MX2020005041A (es) 2017-11-21 2020-10-12 Univ Leland Stanford Junior Agonistas parciales de interleucina-2.
AU2018378078B2 (en) * 2017-12-06 2024-07-25 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
CA3086199A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
AU2018394189B2 (en) 2017-12-27 2023-12-21 Kyowa Kirin Co., Ltd. IL-2 variant
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
WO2019144309A1 (en) * 2018-01-24 2019-08-01 Beijing Percans Oncology Co. Ltd. Cytokine Fusion Proteins
EP3743438A4 (en) 2018-01-24 2022-02-23 Beijing Percans Oncology Co. Ltd. CYTOKI FUSION PROTEINS
US11534479B2 (en) 2018-02-16 2022-12-27 Iltoo Pharma Use of interleukin 2 for treating Sjögren's syndrome
WO2019191295A1 (en) 2018-03-28 2019-10-03 Bristol-Myers Squibb Company Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
EP3552738B1 (en) * 2018-04-12 2024-07-31 Sandvik Machining Solutions AB A method of producing an additive manufactured object
CN120349426A (zh) 2018-06-22 2025-07-22 科优基因公司 白介素-2变体及其使用方法
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
EP4023667A1 (en) 2018-08-06 2022-07-06 Medikine, Inc. Il-2 receptor binding compounds
EP3836954B1 (en) 2018-08-13 2025-05-07 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
US20220056094A1 (en) 2018-12-21 2022-02-24 Jiangsu Hengrui Medicine Co., Ltd. Human interleukin-2 variant or derivative thereof
EP3917962A1 (en) 2019-02-01 2021-12-08 Regeneron Pharmaceuticals, Inc. Anti-il2 receptor gamma antigen-binding proteins
JP2022520632A (ja) 2019-02-15 2022-03-31 インテグラル・モレキュラー・インコーポレイテッド 共通軽鎖を含む抗体及びその使用
AU2020223293A1 (en) 2019-02-15 2021-08-19 Integral Molecular, Inc. Claudin 6 antibodies and uses thereof
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
US11845801B2 (en) 2019-06-12 2023-12-19 AskGene Pharma, Inc. IL-15 prodrugs and methods of use thereof
AU2020323893A1 (en) 2019-07-26 2022-02-17 Visterra, Inc. Interleukin-2 agents and uses thereof
CN114222764B (zh) * 2019-08-12 2025-03-11 奥美药业有限公司 可优先结合IL-2Rα的IL-2融合蛋白
BR112022008750A2 (pt) 2019-11-05 2022-07-19 Medikine Inc Composto de ligação de receptor duplo, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
CA3160133A1 (en) 2019-11-05 2021-05-14 Medikine, Inc. Il-2rbyc binding compounds
EP4073094A1 (en) * 2019-12-12 2022-10-19 Iltoo Pharma Interleukin 2 chimeric constructs
TW202136317A (zh) 2019-12-20 2021-10-01 美商再生元醫藥公司 新穎之ｉｌ２促效劑及其使用方法（二）
EP4090674A4 (en) 2020-01-14 2024-01-24 Synthekine, Inc. Biased il2 muteins methods and compositions
JP2023512687A (ja) 2020-02-03 2023-03-28 メディカイン、インコーポレイテッド ＩＬ－７Ｒα結合化合物
CA3166816A1 (en) 2020-02-03 2021-08-12 William J. Dower Il-7r.alpha..gamma.c binding compounds
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
US11028132B1 (en) 2020-04-07 2021-06-08 Yitzhak Rosen Half-life optimized linker composition
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
GB2621482B (en) 2020-05-13 2024-09-04 Bonum Therapeutics Inc Compositions of protein complexes and methods of use thereof
KR20230060514A (ko) * 2020-09-01 2023-05-04 다케다 야쿠힌 고교 가부시키가이샤 인터루킨-2 뮤테인 및 이의 용도
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
TW202233673A (zh) 2020-10-23 2022-09-01 美商雅雪生物治療公司 含調節免疫細胞功能之ｃｄ８抗原結合分子之融合物
KR20230097094A (ko) 2020-10-29 2023-06-30 브리스톨-마이어스 스큅 컴퍼니 질환의 치료를 위한 융합 단백질
US20230398183A1 (en) 2020-11-13 2023-12-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising human interleukin 2 variant or derivative thereof and use thereof
EP4255466A1 (en) 2020-12-04 2023-10-11 Visterra, Inc. Methods of using interleukin-2 agents
IL304365B2 (en) * 2021-03-31 2025-04-01 Hanmi Pharmaceutical Co Ltd A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof
JP2024514577A (ja) 2021-04-09 2024-04-02 セレクタ バイオサイエンシーズ インコーポレーテッド 免疫寛容を増強するために高親和性ｉｌ－２受容体アゴニストと組み合わせて免疫抑制剤を含む合成ナノキャリア
IL311883A (en) 2021-10-06 2024-06-01 Assist Publique H?Pitaux De Paris Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023133319A1 (en) 2022-01-10 2023-07-13 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
US20230322884A1 (en) 2022-03-09 2023-10-12 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
WO2023183568A1 (en) 2022-03-25 2023-09-28 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
WO2023196566A1 (en) 2022-04-08 2023-10-12 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
CN115322260A (zh) * 2022-06-13 2022-11-11 杭州高田生物医药有限公司 能够在肠道内富集且增殖调节性t细胞的融合蛋白及应用
KR20250113390A (ko) 2022-09-12 2025-07-25 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 자폐 스펙트럼 장애 치료에 사용되는 인터루킨-2
KR20250114330A (ko) 2022-11-30 2025-07-29 인테그럴 몰큘러 인코포레이티드 클라우딘 6을 표적하는 항체 및 이의 이중특이적 형식
KR20250133750A (ko) 2023-01-09 2025-09-08 오디세이 테라퓨틱스, 인코포레이티드 항-tnfr2 항원-결합 단백질 및 그의 용도
WO2024229432A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
WO2024229380A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases
WO2024229350A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes
WO2024229370A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Compositions and methods for treating gvhd
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1599867A (zh) * 2001-12-04 2005-03-23 默克专利有限公司 具有调节的选择性的免疫细胞因子
WO2008003473A2 (en) * 2006-07-06 2008-01-10 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
CN103492411A (zh) * 2011-02-10 2014-01-01 罗切格利卡特公司 突变体白介素-2多肽

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
CA2455013A1 (en) 2001-07-27 2003-02-13 Francesca Storici Systems for in vivo site-directed mutagenesis using oligonucleotides
AU2004251145C1 (en) 2003-06-12 2011-04-14 Eli Lilly And Company GLP-1 analog fusion proteins
US7267960B2 (en) * 2003-07-25 2007-09-11 Amgen Inc. Antagonists and agonists of LDCAM and methods of use
RU2006135112A (ru) * 2004-03-05 2008-04-10 Чирон Корпорейшн (Us) Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
HUE028379T2 (en) * 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
WO2010085495A1 (en) * 2009-01-21 2010-07-29 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
NZ594665A (en) * 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
IL323000A (en) * 2010-03-05 2025-10-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeted for immune modulation
CN102174111B (zh) * 2011-01-25 2013-01-09 江苏省弗泰生物科技有限公司 人白介素2-Fc融合蛋白及其用途
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
JP2014094898A (ja) * 2012-11-07 2014-05-22 Univ Of Tsukuba 炎症性腸疾患に関連する、ＣＤ３００ａ発現細胞の活性調節剤を含有する医薬品、ならびにＣＤ３００ａ遺伝子欠損マウスおよびＣＤ３００ａ発現細胞の活性調節剤の使用
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
DK2970486T3 (en) * 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
CN103193887B (zh) * 2013-04-03 2015-02-04 江苏众红生物工程创药研究院有限公司 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法
IL289475B2 (en) * 2014-07-21 2023-10-01 Delinia Inc Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1599867A (zh) * 2001-12-04 2005-03-23 默克专利有限公司 具有调节的选择性的免疫细胞因子
WO2008003473A2 (en) * 2006-07-06 2008-01-10 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
CN103492411A (zh) * 2011-02-10 2014-01-01 罗切格利卡特公司 突变体白介素-2多肽

Also Published As

Publication number Publication date
EP3172227B9 (en) 2020-01-08
MX2017000821A (es) 2017-08-18
EA038361B1 (ru) 2021-08-13
IL278299B (en) 2022-02-01
KR102493543B1 (ko) 2023-01-30
JP6768633B2 (ja) 2020-10-14
AU2015292889A1 (en) 2016-01-28
AU2020203480A1 (en) 2020-06-18
GB201615553D0 (en) 2016-10-26
EP3172227A4 (en) 2017-12-20
US20210047382A1 (en) 2021-02-18
HUE046065T2 (hu) 2020-01-28
EP3172227B1 (en) 2019-09-04
EA202190903A2 (ru) 2021-07-30
CN106795213A (zh) 2017-05-31
RS59789B1 (sr) 2020-02-28
CA2954847A1 (en) 2016-01-28
JP2021006038A (ja) 2021-01-21
ES2763198T3 (es) 2020-05-27
SG10202010158TA (en) 2020-11-27
EA202190903A3 (ru) 2021-12-31
SG11201700514SA (en) 2017-02-27
IL250024A0 (en) 2017-03-30
JP2017527272A (ja) 2017-09-21
MX2021000083A (es) 2021-03-25
IL250024B (en) 2020-11-30
US20170037102A1 (en) 2017-02-09
IL289475B1 (en) 2023-06-01
GB2538666A (en) 2016-11-23
SI3172227T1 (sl) 2020-02-28
PL3172227T3 (pl) 2020-04-30
MX378790B (es) 2025-03-10
PT3172227T (pt) 2019-12-06
AU2015292889C1 (en) 2023-01-19
DK3172227T3 (da) 2019-12-02
EP3172227A2 (en) 2017-05-31
LT3172227T (lt) 2020-02-10
KR20170028938A (ko) 2017-03-14
US20220112260A1 (en) 2022-04-14
US20170051029A1 (en) 2017-02-23
IL289475A (en) 2022-02-01
AU2022204946A1 (en) 2022-07-28
IL289475B2 (en) 2023-10-01
US20190375812A1 (en) 2019-12-12
EA201790213A1 (ru) 2017-06-30
US20170327555A1 (en) 2017-11-16
EP3587444A1 (en) 2020-01-01
ZA201700344B (en) 2020-08-26
WO2016014428A3 (en) 2016-03-24
CN114133456A (zh) 2022-03-04
AU2015292889B2 (en) 2020-02-27
WO2016014428A2 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
CN106795213B (zh) 选择性地活化调节性t细胞用于治疗自身免疫病的分子
US11535657B2 (en) Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
HK1261663A1 (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
EA041387B1 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки для лечения аутоиммунных заболеваний

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20211207

CF01 Termination of patent right due to non-payment of annual fee